How to Get Repatha (Evolocumab) in Delaware

What Is Repatha and Why Do Delaware Patients Need It

Repatha is a fully human monoclonal antibody that blocks PCSK9, the protein that degrades LDL receptors in the liver. By inhibiting PCSK9, evolocumab restores LDL receptor cycling and lowers LDL-C by 59 to 75 percent on top of statin therapy in most patients [1]. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering [2].

The FOURIER trial (N = 27,564) published in the New England Journal of Medicine in 2017 established the cardiovascular outcome benefit. Patients randomized to evolocumab 140 mg every 2 weeks or 420 mg monthly achieved a 59 percent reduction in LDL-C from a median baseline of 92 mg/dL, reaching a median of 30 mg/dL. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8 percent of the evolocumab group versus 11.3 percent in the placebo group, a relative risk reduction of 15 percent (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [3].

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with very high-risk ASCVD and LDL-C persistently 70 mg/dL or higher on maximally tolerated statin therapy plus ezetimibe, it is reasonable to add a PCSK9 inhibitor" (Class IIa, Level of Evidence A) [4]. Delaware has no additional state-level restriction on PCSK9 prescribing beyond federal FDA labeling.

Who Can Prescribe Repatha in Delaware

Any Delaware-licensed prescriber with full prescriptive authority can write a Repatha order. That includes MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs) operating within their scope. Delaware APRNs hold independent prescriptive authority once they meet the 3-year/3,000-hour collaborative practice requirement under Delaware Code Title 24, Section 1922 [5]. PAs in Delaware may prescribe Schedule II through V controlled substances and non-controlled drugs including biologics under a supervising physician agreement per Delaware Board of Medical Licensure rules [6].

Cardiologists and lipidologists write the majority of Repatha prescriptions nationally, but primary care providers and endocrinologists commonly prescribe it too, especially for patients with HeFH already under their care. Telehealth providers licensed in Delaware can prescribe evolocumab electronically to Delaware patients, provided a valid prescriber-patient relationship is established. Delaware joined the Interstate Medical Licensure Compact in 2015 [7], so physicians licensed in any compact state can obtain a Delaware license through an expedited pathway, expanding the pool of telehealth prescribers available to Delaware residents.

Labs Required Before Starting Repatha in Delaware

A fasting lipid panel is the minimum baseline lab. Most insurers and prior authorization (PA) systems in Delaware also require a documented LDL-C drawn while the patient is on maximally tolerated statin therapy. The ACC/AHA guideline threshold that triggers PCSK9 consideration is an LDL-C at or above 70 mg/dL for very high-risk ASCVD patients despite statin plus ezetimibe [4].

Beyond the lipid panel, most PA forms from Delaware commercial insurers and Delaware Medicaid request:

• A fasting lipid panel dated within 90 days (some plans accept 6 months)
• Documentation of statin therapy at maximum tolerated dose for at least 4 to 12 weeks
• If claiming statin intolerance, records of at least two separate statins trialed and the adverse effects reported
• A qualifying diagnosis confirmed in the chart: ASCVD (ICD-10 codes I25.10, I21.x, I63.x, or similar) or FH (ICD-10 E78.01 for HeFH, E78.02 for HoFH)

Thyroid function (TSH) and a complete metabolic panel are often ordered at baseline to rule out secondary causes of dyslipidemia such as hypothyroidism or nephrotic syndrome, both of which should be treated before escalating lipid therapy [8]. Creatine kinase (CK) is useful if the patient reports any muscle symptoms on prior statin therapy.

The HealthRX clinical team uses a four-item pre-authorization checklist before submitting a Delaware Repatha PA request: (1) LDL-C on maximally tolerated statin documented in the chart with date and value; (2) ezetimibe trial documented or a clinical reason for omission; (3) qualifying diagnosis confirmed by ICD-10 code; (4) most recent cardiovascular risk-stratification note from a cardiology or lipidology visit. Completing all four items before submission reduces first-pass denial rates substantially in our clinical experience.

How to Get a Repatha Prescription in Delaware Step by Step

Getting Repatha prescribed in Delaware follows a predictable sequence, but timing depends on whether prior authorization is needed and whether the patient uses commercial insurance, Medicaid, or pays out of pocket.

Step 1. Schedule a clinical evaluation. Book an appointment with a Delaware-licensed cardiologist, primary care physician, or telehealth provider. Bring any recent lipid panels, a medication list, and records of previous statin trials. Telehealth visits for lipid management qualify as a legitimate clinical encounter under Delaware Division of Professional Regulation guidance [9].

Step 2. Complete baseline labs. Order a fasting lipid panel and any additional tests the prescriber deems necessary. Results should be available within 24 to 72 hours through most Delaware hospital networks or Quest/LabCorp locations statewide.

Step 3. Obtain the prescription. Once the clinical threshold is met, the prescriber sends an electronic prescription to a specialty pharmacy. Repatha is a specialty biologic and is typically dispensed through specialty pharmacy channels such as Accredo, CVS Specialty, or a hospital-affiliated specialty pharmacy rather than a standard retail chain [10].

Step 4. Complete prior authorization. For commercially insured and Medicaid patients, the specialty pharmacy or prescriber's office initiates PA. Delaware Medicaid requires PA for Repatha under the preferred drug list, with coverage confirmed for HeFH and established ASCVD when documentation criteria are met [11]. Commercial plans including Highmark Delaware and Aetna (active in Delaware's ACA marketplace) follow similar PA structures aligned with ACC/AHA criteria [4].

Step 5. Receive the medication. If PA is approved, the specialty pharmacy ships Repatha overnight in a temperature-controlled package. Evolocumab requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) but may be stored at room temperature up to 77 degrees Fahrenheit for up to 30 days [2]. Most Delaware patients report receiving their first supply within 3 to 7 business days after approval.

Telehealth Options for Getting Repatha in Delaware

Delaware permits telehealth prescribing of non-controlled medications including biologics such as evolocumab. The Delaware Telehealth Access Act (Title 16, Chapter 97) requires that telehealth services meet the same standard of care as in-person services and that a valid provider-patient relationship exist before prescribing [12].

Telehealth platforms operating in Delaware can conduct a synchronous video visit to evaluate a patient's cardiovascular risk, review uploaded lab results, and prescribe Repatha if clinical criteria are satisfied. This is particularly useful for patients in rural Delaware counties such as Sussex or Kent, where access to academic lipidology programs is limited. The Christiana Care Health System in Wilmington and Bayhealth operate telehealth services within Delaware, and national telehealth platforms credentialed in Delaware also serve this need [13].

One practical consideration: some telehealth platforms do not handle specialty pharmacy coordination in-house. Patients should confirm before booking whether the platform will manage the PA submission or whether they will need to coordinate that step themselves through their insurer.

Prior Authorization Requirements in Delaware

Prior authorization is nearly universal for Repatha across Delaware payers. A 2020 analysis published in JAMA Cardiology found that approval rates for PCSK9 inhibitor PA requests nationally were 46 percent on first submission, rising to 79 percent after appeal, with denial most often citing inadequate statin trial documentation [14]. Delaware-specific data mirror this national pattern.

The ACC's 2019 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "Clinicians should document maximal statin use, LDL-C response, and cardiovascular risk category to support PCSK9 inhibitor prescribing and payer approval" [15]. That documentation is precisely what Delaware PA forms require.

Key elements Delaware payers typically require for Repatha PA approval:

• Diagnosis of HeFH, HoFH, or established ASCVD confirmed in chart notes
• LDL-C result on current statin therapy (most plans want the value drawn within 90 days)
• Evidence of high-intensity or maximally tolerated statin use (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg preferred per AHA/ACC guidelines) [16]
• Ezetimibe co-therapy documented or a contraindication stated
• For statin-intolerant claims: two or more statins trialed, each with documented adverse effect and dose

Appeals succeed most often when the prescriber submits a detailed clinical letter referencing the FOURIER outcome data [3] and the ACC/AHA guideline recommendation tier [4]. Delaware Medicaid allows one level of internal appeal and an external independent review if the internal appeal is denied.

Repatha Costs and Assistance Programs in Delaware

The list price for Repatha 140 mg/mL SureClick autoinjector is approximately $652 per month (two pens) or $758 per month for the 420 mg monthly Pushtronex system as of 2024 [2]. Out-of-pocket costs for commercially insured Delaware patients are typically far lower with manufacturer support.

Amgen's Repatha Copay Card reduces monthly cost to as low as $5 for eligible commercially insured patients, with Amgen covering up to $3,600 per year [17]. Patients on Medicare or Medicaid do not qualify for the copay card under federal anti-kickback rules, but Amgen's PCSK9 Patient Assistance Program (PAP) provides Repatha at no cost to uninsured or underinsured patients meeting income criteria (generally at or below 600 percent of the federal poverty level) [17].

Delaware Medicaid (Delaware Medical Assistance Program, DMAP) covers Repatha with PA. Once PA is granted, patient cost-sharing under Medicaid is minimal, typically $1 to $4 per prescription fill for most Delaware Medicaid enrollees [11]. The Delaware Insurance Commissioner also maintains a Prescription Assistance program directory for residents who need additional support navigating drug costs [18].

Transferring a Repatha Prescription to Delaware

Patients moving to Delaware from another state with an existing Repatha prescription can transfer the script in several ways. Because Repatha is a specialty biologic, most transfers happen at the specialty pharmacy level rather than at a retail counter.

If the patient uses a national specialty pharmacy (Accredo, CVS Specialty, Walgreens Specialty), the existing account can be updated to a Delaware shipping address without a new prescription, provided the original prescription still has valid refills and the prescriber is licensed to prescribe in their original state. However, Delaware pharmacies dispensing to Delaware residents must verify that the prescribing provider holds active licensure; out-of-state prescribers whose license does not include Delaware coverage through a compact agreement may need to transfer care to a Delaware-licensed provider [9].

Delaware's Board of Pharmacy (Title 24, Chapter 25) does not restrict the importation of specialty medications from out-of-state licensed pharmacies for personal use, so patients receiving Repatha via mail-order specialty pharmacy from a licensed out-of-state 503B outsourcing facility or manufacturer-authorized distributor face no state-level barrier [19]. For compounded PCSK9 biologics, the situation differs: 503A compounding pharmacies in Delaware may prepare patient-specific preparations, but compounded biosimilar PCSK9 inhibitors are not pharmacologically equivalent to evolocumab and are not FDA-approved substitutes [20].

What to Expect After Starting Repatha in Delaware

Evolocumab begins lowering LDL-C within the first week of dosing. In FOURIER, LDL-C reduction was maximal by week 4 and sustained throughout the 2.2-year median follow-up [3]. A repeat fasting lipid panel 4 to 8 weeks after the first injection confirms the therapeutic response and provides the documentation most Delaware insurers require for PA renewal.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol recommends checking a fasting lipid panel 4 to 12 weeks after starting or adjusting lipid-lowering therapy, then every 3 to 12 months thereafter [16]. Delaware prescribers should schedule this follow-up lab before the PA renewal window opens, typically at 6 months for commercial plans and at 12 months for Delaware Medicaid.

Common injection-site reactions occur in about 2.1 percent of patients in clinical trial data versus 1.6 percent for placebo [3]. Serious adverse events were not significantly elevated over placebo in FOURIER. Neurocognitive adverse events, raised as a theoretical concern with very low LDL-C levels, were formally evaluated in the EBBINGHAUS sub-study (N = 1,204): no significant difference in cognitive function was found between the evolocumab and placebo groups at any time point [21].

Patients self-injecting at home should store unused Repatha pens in the refrigerator, allow each pen to reach room temperature for 30 minutes before injection, and rotate injection sites (abdomen, thigh, or upper arm) [2]. Delaware home health agencies can provide injection training if needed, particularly for older patients or those with dexterity limitations.

Delaware Pharmacy Options for Dispensing Repatha

Repatha is classified as a specialty medication and is not stocked at most retail pharmacies in Delaware. Specialty pharmacy channels used by Delaware patients include:

Accredo (specialty arm of Cigna/Express Scripts) ships to all Delaware ZIP codes with overnight temperature-controlled delivery. CVS Specialty operates a Delaware-licensed specialty pharmacy and integrates PA services directly for CVS/Caremark members. Walgreens Specialty Pharmacy handles mail-order Repatha for BCBS Delaware and other commercial plans. Christiana Care's outpatient pharmacy in Newark, DE is licensed as a specialty pharmacy and can dispense Repatha to patients seen within the Christiana Care system [13].

503A compounding pharmacies in Delaware are licensed and may prepare certain patient-specific formulations, but as stated above, compounded versions of evolocumab do not exist as a legitimate substitute for the FDA-approved biologic product [20]. Any offer of "compounded Repatha" from a Delaware 503A pharmacy would not represent the same molecule and should be reported to the Delaware Board of Pharmacy.